Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950134-06-020589
Filing Date
2006-11-06
Accepted
2006-11-06 16:55:25
Documents
4
Period of Report
2005-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO FORM 10-K d40894e10vkza.htm 10-K/A 29830
2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM d40894exv23w1.htm EX-23.1 1798
3 CERTIFICATION OF CEO AND CFO PURSUANT TO RULE 13A-14(A) AND RULE 15D-14(A) d40894exv31w1.htm EX-31.1 14385
4 CERTIFICATION OF CEO AND CFO PURSUANT TO SECTION 906 d40894exv32w1.htm EX-32.1 5716
  Complete submission text file 0000950134-06-020589.txt   53125
Mailing Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701
Business Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701 5127089310
INTROGEN THERAPEUTICS INC (Filer) CIK: 0001018710 (see all company filings)

EIN.: 742704230 | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-21291 | Film No.: 061190971
SIC: 2834 Pharmaceutical Preparations